Figure 6.

Growth delay of the patient-derived xenograft, BL0382 bladder carcinoma grown as a subcutaneous xenograft in female NSG mice with each of five cytidine analogs administered in optimized dose and route regimens. Experiments were initiated with groups of 7–8 mice at 6–7 weeks of age and when tumors were 150–200 mm³ in volume. Data are the mean and standard error for each group (n=16 for vehicle control; n = 8/drug treated group) with data no longer plotted when 50% or less of the animals remained within each group. Mean body weights of groups of mice over the course of the experiment for each treatment group are shown in chart 2.